Gaowei Huang

Gaowei Huang

Auto-generated profile, based on publicly available information

Gaowei Huang

Department of Urology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2025 in Cancer Research
Verified
Journal Article
Closed access
JLJinwen Liu
Jinwen Liu
GHGaowei Huang
Gaowei Huang
HLHao Lin
Hao Lin
RYRui Yang
Rui Yang
WZWenhao Zhan
Wenhao Zhan
BHBin Huang
Bin Huang
Sunitinib is a first-line targeted therapy for patients with renal cell carcinoma (RCC), but resistance represents a significant obstacle to the treatment of advanced and metastatic RCC. Metabolic reprogramming is a characteristic of RCC, and changes in metabolic processes might contribute to resistance to sunitinib. In this study, we identified methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a mitochondrial enzyme involved in one-carbon metabolism, as a critical mediator of sunitinib resistance in RCC. MTHFD2 was elevated in sunitinib-resistant RCC cells, and loss of MTHDF2 conferred sensitivity to sunitinib. In patients, MTHFD2 was highly expressed in RCC and was associated with poor outcomes. Mechanistically, MTHFD2 stimulated UDP-N-acetylglucosamine (UDP-GlcNAc) biosynthesis and promoted cMYC O-GlcNAcylation by driving the folate cycle. O-GlcNAcylation enhanced cMYC stability and promoted MTHFD2 and cyclin D1 transcription. Targeting MTHFD2 or cyclin D1 sensitized tumor cells to sunitinib in vitro and in vivo. Consistently, development of a peptide drug capable of efficiently degrading MTHFD2 enabled reversal of sunitinib resistance in RCC. These findings identify a noncanonical metabolic function of MTHFD2 in cell signaling and response to therapy and reveal the interplay between one-carbon metabolism and sunitinib resistance in RCC. Targeting MTHFD2 could be an effective approach to overcome sunitinib resistance. Significance: MTHFD2 regulates cMYC O-GlcNAcylation to promote sunitinib resistance in renal cell carcinoma, highlighting the important role of one-carbon metabolism in sunitinib resistance and proposing therapeutic strategies to improve patient outcomes.

14 March 2025
Verified
Other
Open access
JLJinwen Liu
Jinwen Liu
GHGaowei Huang
Gaowei Huang
HLHao Lin
Hao Lin
RYRui Yang
Rui Yang
WZWenhao Zhan
Wenhao Zhan
BHBin Huang
Bin Huang
Supplementary Data 2 from MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma

14 March 2025
Verified
Other
Open access
JLJinwen Liu
Jinwen Liu
GHGaowei Huang
Gaowei Huang
HLHao Lin
Hao Lin
RYRui Yang
Rui Yang
WZWenhao Zhan
Wenhao Zhan
BHBin Huang
Bin Huang
Sunitinib resistant cell RNA_seq data

17 June 2026
Verified
Other
Open access
JLJinwen Liu
Jinwen Liu
GHGaowei Huang
Gaowei Huang
HLHao Lin
Hao Lin
RYRui Yang
Rui Yang
WZWenhao Zhan
Wenhao Zhan
BHBin Huang
Bin Huang
Sunitinib is a first-line targeted therapy for patients with renal cell carcinoma (RCC), but resistance represents a significant obstacle to the treatment of advanced and metastatic RCC. Metabolic reprogramming is a characteristic of RCC, and changes in metabolic processes might contribute to resistance to sunitinib. In this study, we identified methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a mitochondrial enzyme involved in one-carbon metabolism, as a critical mediator of sunitinib resistance in RCC. MTHFD2 was elevated in sunitinib-resistant RCC cells, and loss of MTHDF2 conferred sensitivity to sunitinib. In patients, MTHFD2 was highly expressed in RCC and was associated with poor outcomes. Mechanistically, MTHFD2 stimulated UDP-N-acetylglucosamine (UDP-GlcNAc) biosynthesis and promoted cMYC O-GlcNAcylation by driving the folate cycle. O-GlcNAcylation enhanced cMYC stability and promoted MTHFD2 and cyclin D1 transcription. Targeting MTHFD2 or cyclin D1 sensitized tumor cells to sunitinib in vitro and in vivo. Consistently, development of a peptide drug capable of efficiently degrading MTHFD2 enabled reversal of sunitinib resistance in RCC. These findings identify a noncanonical metabolic function of MTHFD2 in cell signaling and response to therapy and reveal the interplay between one-carbon metabolism and sunitinib resistance in RCC. Targeting MTHFD2 could be an effective approach to overcome sunitinib resistance.Significance:MTHFD2 regulates cMYC O-GlcNAcylation to promote sunitinib resistance in renal cell carcinoma, highlighting the important role of one-carbon metabolism in sunitinib resistance and proposing therapeutic strategies to improve patient outcomes.

14 March 2025
Verified
Other
Open access
JLJinwen Liu
Jinwen Liu
GHGaowei Huang
Gaowei Huang
HLHao Lin
Hao Lin
RYRui Yang
Rui Yang
WZWenhao Zhan
Wenhao Zhan
BHBin Huang
Bin Huang
Figure S1-S17,Table S1-S2,Supplementary methods